Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cocrystal Pharma Inc
COCP | US
2.10
USD0.03
1.36%
COCP | US
About Cocrystal Pharma Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.10
Open
2.10
High
2.11
Low
2.04
Cocrystal Pharma Inc. a biotechnology company focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV) influenza virus coronavirus and norovirus infections. The company develops CC-31244 a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344 a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell Washington.
View LessCOCP | US
Risk
86.6
Sharpe
0.15
Luna's Score
54/100
Recommendation
Hold
Luna says (COCP | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
107.4%1 month
86.6%3 months
81.6%6 months
77.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.19
Debt to equity
0.10
Debt to assets
0.08
Ent. to EBITDA
0.66
Ent. to rev.
17.89
PEG
-
Other Fundamentals
EBITDA
-21.15M
MarketCap
21.36M
MarketCap(USD)
21.36M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
26.90
Ret. on equity
-68.86
Short ratio
4.69
Short perc.
0.77
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.72
Range1M
0.83
Range3M
0.85
Volumes: Market Activity
Rel. volume
0.33
Price X volume
13.76K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.66 | - | Expensive |
| Ent. to Revenue | 17.89 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.19 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 81.60 | - | Par |
| Debt to Equity | 0.10 | -1.23 | Expensive |
| Debt to Assets | 0.08 | 0.25 | Cheaper |
| Market Cap | 21.36M | - | Emerging |
